<DOC>
	<DOCNO>NCT00003334</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine doxorubicin paclitaxel treat patient recurrent refractory endometrial cancer , fallopian tube cancer , sarcoma female reproductive tract .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Endometrial Cancer , Fallopian Tube Cancer , Sarcoma Female Reproductive Tract</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate duration response doxorubicin HCl liposome paclitaxel patient endometrial cancer , tubal cancer , sarcoma carcinosarcoma ( mixed mesodermal tumor ) gynecologic origin . II . Define safety profile combination doxorubicin HCl liposome paclitaxel patient population . OUTLINE : Patients stratify two group . Group 1 consist patient untreated endometrial tubal cancer Group 2 consist patient sarcomas carcinosarcoma ( mixed mesodermal tumor ) gynecologic origin subdivide prior therapy . Patients receive doxorubicin HCl liposome intravenously day 1 treatment course . Paclitaxel administer intravenously weekly day 1 , 8 , 15 course . Courses repeat every 21 day . Treatment continue absence unacceptable toxic effect disease progression . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 28-60 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm recurrent refractory carcinoma endometrium fallopian tube sarcomas gynecologic origin include mixed mesodermal sarcoma Documented recurrence persistence disease appropriate surgical and/or radiation therapy Measurable evaluable disease PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Platelet count least 50,000/mm3 Granulocyte count least 1,000/mm3 Hepatic : SGOT SGPT great 3 time upper limit normal ( ULN ) Bilirubin great 3 time ULN Renal : Creatinine le 2.5 mg/dL Cardiovascular : MUGA least low limit normal Normal ejection fraction and/or stable cardiac status Other : No medical social factor would interfere compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious concurrent illness require immediate therapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 month since prior combine modality adjuvant chemotherapy Prior doxorubicin allow cumulative dose record Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : At least 30 day since prior noncytotoxic experimental antiemetic antifungal investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine carcinosarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>endometrial stromal sarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>ovarian carcinosarcoma</keyword>
</DOC>